Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey.

Kosa RE, Lazzaro S, Bi YA, Tierney B, Gates D, Modi S, Costales C, Rodrigues AD, Tremaine LM, Varma MV.

Drug Metab Dispos. 2018 Jun 7. pii: dmd.118.081794. doi: 10.1124/dmd.118.081794. [Epub ahead of print]

PMID:
29880631
2.

Predicting Human Clearance of Organic Anion Transporting Polypeptide Substrates Using Cynomolgus Monkey: In Vitro-In Vivo Scaling of Hepatic Uptake Clearance.

De Bruyn T, Ufuk A, Cantrill C, Kosa RE, Bi YA, Niosi M, Modi S, Rodrigues AD, Tremaine LM, Varma MVS, Galetin A, Houston JB.

Drug Metab Dispos. 2018 Jul;46(7):989-1000. doi: 10.1124/dmd.118.081315. Epub 2018 May 2.

PMID:
29720472
3.

In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey.

Ufuk A, Kosa RE, Gao H, Bi YA, Modi S, Gates D, Rodrigues AD, Tremaine LM, Varma MVS, Houston JB, Galetin A.

J Pharmacol Exp Ther. 2018 Jun;365(3):688-699. doi: 10.1124/jpet.118.247767. Epub 2018 Apr 11.

PMID:
29643253
4.

Hepatobiliary Clearance Prediction: Species Scaling From Monkey, Dog, and Rat, and In Vitro-In Vivo Extrapolation of Sandwich-Cultured Human Hepatocytes Using 17 Drugs.

Kimoto E, Bi YA, Kosa RE, Tremaine LM, Varma MVS.

J Pharm Sci. 2017 Sep;106(9):2795-2804. doi: 10.1016/j.xphs.2017.04.043. Epub 2017 Apr 27.

PMID:
28456723
5.

Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides.

Thakare R, Gao H, Kosa RE, Bi YA, Varma MVS, Cerny MA, Sharma R, Kuhn M, Huang B, Liu Y, Yu A, Walker GS, Niosi M, Tremaine L, Alnouti Y, Rodrigues AD.

Drug Metab Dispos. 2017 Jul;45(7):721-733. doi: 10.1124/dmd.117.075275. Epub 2017 Apr 10.

PMID:
28396527
6.

Novel Method to Predict In Vivo Liver-to-Plasma Kpuu for OATP Substrates Using Suspension Hepatocytes.

Riccardi K, Lin J, Li Z, Niosi M, Ryu S, Hua W, Atkinson K, Kosa RE, Litchfield J, Di L.

Drug Metab Dispos. 2017 May;45(5):576-580. doi: 10.1124/dmd.116.074575. Epub 2017 Mar 3.

7.

Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate.

Bhattacharya SK, Andrews K, Beveridge R, Cameron KO, Chen C, Dunn M, Fernando D, Gao H, Hepworth D, Jackson VM, Khot V, Kong J, Kosa RE, Lapham K, Loria PM, Londregan AT, McClure KF, Orr ST, Patel J, Rose C, Saenz J, Stock IA, Storer G, VanVolkenburg M, Vrieze D, Wang G, Xiao J, Zhang Y.

ACS Med Chem Lett. 2014 Feb 24;5(5):474-9. doi: 10.1021/ml400473x. eCollection 2014 May 8.

8.

Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide).

Tseng E, Walsky RL, Luzietti RA Jr, Harris JJ, Kosa RE, Goosen TC, Zientek MA, Obach RS.

Drug Metab Dispos. 2014 Jul;42(7):1163-73. doi: 10.1124/dmd.114.057000. Epub 2014 Apr 15.

9.

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

Pfefferkorn JA, Guzman-Perez A, Litchfield J, Aiello R, Treadway JL, Pettersen J, Minich ML, Filipski KJ, Jones CS, Tu M, Aspnes G, Risley H, Bian J, Stevens BD, Bourassa P, D'Aquila T, Baker L, Barucci N, Robertson AS, Bourbonais F, Derksen DR, Macdougall M, Cabrera O, Chen J, Lapworth AL, Landro JA, Zavadoski WJ, Atkinson K, Haddish-Berhane N, Tan B, Yao L, Kosa RE, Varma MV, Feng B, Duignan DB, El-Kattan A, Murdande S, Liu S, Ammirati M, Knafels J, Dasilva-Jardine P, Sweet L, Liras S, Rolph TP.

J Med Chem. 2012 Feb 9;55(3):1318-33. doi: 10.1021/jm2014887. Epub 2012 Jan 24.

PMID:
22196621
10.

Intrinsic electrophilicity of the 4-methylsulfonyl-2-pyridone scaffold in glucokinase activators: role of glutathione-S-transferases and in vivo quantitation of a glutathione conjugate in rats.

Litchfield J, Sharma R, Atkinson K, Filipski KJ, Wright SW, Pfefferkorn JA, Tan B, Kosa RE, Stevens B, Tu M, Kalgutkar AS.

Bioorg Med Chem Lett. 2010 Nov 1;20(21):6262-7. doi: 10.1016/j.bmcl.2010.08.095. Epub 2010 Aug 21.

PMID:
20829042
11.

Impact of time-dependent inactivation on the estimation of enzyme kinetic parameters for midazolam.

Giragossian C, LaPerle J, Kosa RE, Gillian S.

Drug Metab Lett. 2009 Jan;3(1):45-53.

PMID:
19356116
12.

Kinetics of plasma fructose and glucose when lactose and fructose are used as energy supplements for neonatal calves.

Keller HL, Gherman LI, Kosa RE, Borger DC, Weiss WP, Willett LB.

J Anim Sci. 1998 Aug;76(8):2197-204.

PMID:
9734872
13.

Modification of cell surfaces by enzymatic introduction of special sialic acid analogues.

Kosa RE, Brossmer R, Gross HJ.

Biochem Biophys Res Commun. 1993 Feb 15;190(3):914-20.

PMID:
8439340

Supplemental Content

Support Center